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Aims: Explore the efficacy, safety and tolerability of the dual sodium–glucose
cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes
mellitus (T2DM) and heart failure.
Methods: This multicentre, parallel-group phase IIA study randomized 125 patients
with T2DM and heart failure (New York Heart Association II–IV; plasma N-terminal
pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg,
10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients com-
pleted the study). The primary endpoint was change from baseline in NT-proBNP
after 12 weeks. Secondary endpoints included change from baseline in glycated
haemoglobin, fasting plasma glucose, weight, blood pressure, fasting lipid profile,
high-sensitivity c-reactive protein, and safety and tolerability.
Results: Licogliflozin 10 mg for 12 weeks significantly reduced NT-proBNP vs pla-
cebo (Geometric mean ratio 0.56 [95% confidence interval: 0.33, 0.95], P = .033). A
trend was observed with 50 mg licogliflozin (0.64 [95% confidence interval: 0.40,
1.03], P = .064), with no difference between licogliflozin and empagliflozin. The larg-
est numerical decreases in glycated haemoglobin were with licogliflozin 50 mg
(−0.58 ± 0.34%) and empagliflozin (−0.44 ± 1.18%) vs placebo (−0.04 ± 0.91%). The
reduction in body weight was similar with licogliflozin 50 mg (−2.15 ± 2.40 kg) and
empagliflozin (−2.25 ± 1.89 kg). A numerical reduction in systolic blood pressure was
seen with licogliflozin 50 mg (−9.54 ± 16.88 mmHg) and empagliflozin
(−6.98 ± 15.03 mmHg) vs placebo (−2.85 ± 11.97 mmHg). Adverse events (AEs) were
mild, including hypotension (6.5%), hypoglycaemia (8.1%) and inadequate diabetes
control (1.6%). The incidence of diarrhoea (4.9%) was lower than previously reported.
Conclusion: The reduction in NT-proBNP with licogliflozin suggests a potential bene-
fit of SGLT1 and 2 inhibition in patients withT2DM and heart failure.
The authors confirm that the PI for this paper is Prof Rudolf A. de Boer and that he had
direct clinical responsibility for patients.
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1 | INTRODUCTION
Type-2 diabetes mellitus (T2DM) is associated with a high risk of car-
diovascular (CV) disease and related complications, such as heart fail-
ure (HF). T2DM is associated with an increased incidence of HF and
the risk of HF hospitalizations/mortality is higher in patients with the
condition compared to those without.1–3 HF is among the most com-
mon CV complications of T2DM, with an incidence greater than that
of myocardial infarction (MI) or stroke.4
Selective sodium–glucose cotransporter (SGLT2) inhibitors have
been developed as antidiabetes drugs and lead to a reduction in gly-
cated haemoglobin (HbA1c) of up to 1%.
5,6 A striking CV benefit of
SGLT2 inhibitors has recently been demonstrated in patients with
T2DM at high risk for CV events, where a significant reduction in the
major adverse cardiac events endpoint (MACE, a composite of CV
death, nonfatal MI and nonfatal stroke) and a reduction in HF hospi-
talizations was seen with empagliflozin and canagliflozin.7,8 Further
evidence was provided in a more recent study, which demonstrated a
reduced risk of the composite of CV death or HF hospitalizations with
dapagliflozin treatment,9 a benefit driven by a reduction in HF hospi-
talizations. These findings are supported by the results of a recent,
real-world evidence study.10 The specific mechanisms underlying the
benefit associated with SGLT2 inhibitors are unclear, but may be
attributed to specific effects of SGLT2 inhibition on renal sodium and
glucose handling,11 which include the switch of cardiac metabolism
from free fatty acid oxidation to β-hydroxybutyrate oxidation,
enhanced oxygen supply due to haemoconcentration,12 and inhibition
of sodium-hydrogen exchange.13 Since HF is the most frequent CV
complication of T2DM, several large-scale trials have been designed
to determine a potential benefit of SGLT2 inhibitors in patients with
HF.14–17
Licogliflozin is a combined inhibitor of SGLT1 and SGLT2 and is
hypothesized to further enhance the effects on renal sodium and glu-
cose handling via inhibition of both cotransporter subtypes in the
proximal renal tubule.18 SGLT1 is also expressed in the small intestine,
where it is required for glucose and galactose absorption. Enteric inhi-
bition of SGLT1 has the potential of achieving weight loss through
glucose and galactose malabsorption,19 calorie wasting and other
potential endocrine-based mechanisms.18 Dual SGLT1 and 2 inhibitors
have been shown to improve HbA1c in patients with T2DM20 and to
have beneficial effects on body weight in both patients with T2DM
and patients with obesity.18,20 SGLT1 receptors are also specifically
expressed in the human heart, although the role of their expression in
this tissue is not fully understood.21,22
The aim of this study was to assess the efficacy (including N-
terminal pro b-type natriuretic peptide [NT-proBNP] measurement as
a surrogate parameter for HF severity), safety and tolerability of
licogliflozin in patients withT2DM, cardiac disease and HF.
2 | METHODS
2.1 | Study design and oversight
This multicentre, double-blind, double-dummy, parallel-group phase II
study randomized patients to 1 of 3 doses of licogliflozin, placebo or
empagliflozin (Figure 1). The trial was conducted in 55 centres across
21 countries. Patients meeting all the eligibility criteria at screening
were entered into the placebo run-in period, where they received sin-
gle blind placebo medication for 2 weeks (to familiarize with the
study-drug intake schedule and to allow correction of any hypo-
volaemia). Eligible patients were then randomized to either
licogliflozin (2.5, 10 or 50 mg once daily [qd], taken at bedtime),
empagliflozin (up-titrated from 10 to 25 mg qd after 2 weeks to mini-
mize potential adverse effects—taken in the morning) or their
What is already known about this subject
• Sodium–glucose cotransporter (SGLT2) inhibitors have
been associated with reduced cardiovascular risk, includ-
ing reduction in heart failure hospitalizations. However,
the mechanism underlying these effects remains unclear.
There are also limited data on the effect on N-terminal
pro b-type natriuretic peptide (NT-proBNP), a biomarker
of cardiac wall stress that is commonly elevated in
patients with heart failure.
• SGLT1 and 2 inhibition with licogliflozin has shown bene-
ficial effects on glucose handling in patients with type-2
diabetes mellitus (T2DM) and on body weight in patients
with obesity
• However, the effects of SGLT1 and 2 inhibition in
patients withT2DM and heart failure are unknown
What this study adds
• This is the first study to evaluate the effects of SGLT1
and 2 inhibition on NT-proBNP in patients with T2DM
and heart failure, with results showing significant reduc-
tions in NT-proBNP with licogliflozin vs placebo
• Secondary analyses suggest reductions in glycated
haemoglobin, body weight and systolic blood pressure
following treatment with licogliflozin, in line with previ-
ously published data
• Licogliflozin treatment was safe and well-tolerated, with
no new safety findings reported
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corresponding placebo (morning or night). Licogliflozin 50 mg was
chosen as the highest dose in this study, based on the previous proof
of concept study, in which a urinary glucose excretion (UGE) over
24 hours of ~100 g was observed following once daily dosing with
licogliflozin 15 mg in patients with T2DM.18 Gastrointestinal tolerabil-
ity was also better with lower doses of licogliflozin (30 mg qd vs
150 mg qd).18 Empagliflozin was included as a comparator due to its
known CV benefit in patients withT2DM.8
Following randomization, patients attended the study site again
at 12 weeks for the evaluation of efficacy (change in NT-proBNP),
safety and tolerability. Following the last study visit at week
12, patients continued with the same assigned treatment for a further
24 weeks. Long-term efficacy, tolerability and safety were planned for
evaluation. This study was prematurely discontinued due to slow
enrolment. Only a limited number of patients had completed the core
12-week period of the study when the study was stopped (n = 44),
with just 1 patient completing the originally planned 24-week follow-
up period. Therefore, the interpretation of the data presented is
mainly descriptive and limited to the main study period, i.e. the first
12 weeks.
This study was designed and implemented in accordance with
ICH Harmonized Tripartite Guidelines for Good Clinical Practice
and according to the ethical principles of the Declaration of Hel-
sinki. Ethical approval was obtained from the Institutional Review
Board/Independent Ethics Committee of each centre where
patients were recruited. All patients provided written informed con-
sent for participation prior to randomization. Site monitoring was
carried out by Novartis. The study investigator (or a designated
staff member) was responsible for data collection and reporting.
The study sponsor had access to the trial database and performed
statistical analyses. All authors had full access to the study data
and had the final responsibility for the decision to submit this man-
uscript for publication.
2.2 | Participants
The goal was to randomize approximately 496 patients, with 125 ran-
domized before early study termination. Patients (≥ 18 years) with
T2DM, with HbA1c ≥ 6.5% and ≤ 10%, and a body mass index of
≥22 kg/m2 at screening were included in this study. Eligible patients
were also required to have an estimated glomerular filtration rate
≥45 mL/min/1.73m2, plasma NT-proBNP >300 pg/mL and docu-
mented symptomatic chronic HF (New York Heart Association
[NYHA] II–IV) at screening. Those receiving angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid
receptor antagonists, angiotensin receptor–neprilysin inhibitors
and/or β-blockers were required to be on stable doses.
Patients with type 1 diabetes, monogenic diabetes, diabetes
resulting from pancreatic injury or secondary forms of diabetes were
excluded from this study. Other key exclusion criteria included a his-
tory of ketoacidosis, recent MI or CV intervention, or low blood pres-
sure (BP; systolic BP ≤ 100 mmHg). The full list of inclusion and
exclusion criteria can be found in the Appendix.
2.3 | Study procedures
At the end of the run-in period, participants were randomized to
either licogliflozin (2.5 mg, 10 mg or 50 mg qd in a 1:1:2 ratio),
empagliflozin (:2 ratio) or placebo (:2 ratio). Randomization was per-
formed with the help of a centralized computer system (Interactive
F IGURE 1 Study design. qd, once a day
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ResponseTechnology) with patients stratified according to geographi-
cal region and left ventricular ejection fraction (LVEF: <45% vs ≥45%).
All doses of licogliflozin (tablets), empagliflozin (over-encapsulated
tablet) or corresponding placebo were administered orally twice daily.
In the licogliflozin treatment arm, 1 licogliflozin tablet was taken at
bedtime and the corresponding empagliflozin placebo (capsule) was
taken in the morning (with or without food). In the empagliflozin arm,
1 empagliflozin capsule was taken in the morning and the
corresponding licogliflozin placebo was taken at bedtime. Patients in
the corresponding placebo arm took 1 capsule in the morning and
1 tablet at bedtime (double-dummy design).
For assessment of efficacy, NT-proBNP was evaluated at baseline
and following 12 weeks of treatment. Other efficacy parameters
included HbA1c, fasting plasma glucose (FPG), lipids, high-sensitivity
C-reactive protein (hsCRP), body weight, body mass index, blood pres-
sure (SBP, DBP) and NYHA class. Left atrial size and volume were
assessed by echocardiography at week −2 (run-in) and week 12. All
assessments were completed and analysed at a central laboratory.
Safety assessments included collection of all adverse events (AEs)
and serious AEs along with their severity and relationship to study
drug, and pregnancies. Haematology, blood chemistry and urine as
well as vital signs, physical condition and body weight were regularly
monitored. Suspected cases of ketoacidosis were reviewed by a
Ketoacidosis Adjudication Committee.
2.4 | Study endpoints
The primary endpoint was the change from baseline in NT-proBNP
relative to placebo following 12-weeks of treatment. Secondary end-
points included the effects of licogliflozin vs placebo at 12 weeks on
HbA1c, FPG, weight, BP, lipids, hsCRP, urinary glucose and sodium
excretion, echocardiography and NYHA class, and the effects of
licogliflozin vs empagliflozin on the same. Safety and tolerability over
12-weeks were also assessed. Key exploratory endpoints included
comparison of licogliflozin vs empagliflozin at 12 weeks on change
from baseline in NT-proBNP, echocardiographic parameters and
NYHA class.
2.5 | Statistical analysis
The study was designed to randomize 496 patients in total, aiming to
provide sufficient power to detect a dose response signal in NT-
proBNP (based on log-transformed ratio of NT-proBNP at week
12 compared to baseline), using Multiple Comparison Procedure-
Modelling (MCP-MOD).23,24 Due to early study termination and a
smaller sample size than originally planned, a mixed effect model of
repeated measures was performed in place of the MCP-MOD, as an
exploratory analysis for NT-proBNP. The change from baseline in log-
transformed NT-proBNP was used as the outcome variable. The
model included LVEF at baseline (<45% vs ≥45%), treatment group
(licogliflozin 2.5, 10 or 50 mg qd, empagliflozin, or placebo), visit and
treatment group-by-visit interaction as fixed-effect factors, baseline
log-transformed NT-proBNP as a covariate, and an unstructured,
within-subject covariance. NT-proBNP data up to week 12 were
included in the model. The adjusted mean differences (back-
transformed as ratios) for each treatment group at week 4 and week
12 were estimated from this model. A P-value <.05 (2-sided) was con-
sidered statistically significant. Statistical comparisons between the
secondary endpoint data were not tested due to the limited sample
sizes. Patient disposition, demographics, and primary and secondary
efficacy analyses are described using summary statistics.
2.6 | Role of the funding source
Novartis sponsored the study, designed the study and analysed
the data.
2.7 | Data sharing statement
Novartis is committed to sharing, with qualified external researchers,
access to patient-level data and supporting clinical documents from
eligible studies. These requests are reviewed and approved by an
independent review panel on the basis of scientific merit. All data pro-
vided are anonymized to respect the privacy of patients who have
participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process
described on www.clinicalstudydatarequest.com.
2.8 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY,25 and are permanently archived in the Concise Guide to
PHARMACOLOGY 2019/20.26
3 | RESULTS
3.1 | Patient disposition and characteristics
Of the 142 patients enrolled in the run-in for this this study, 125 were
randomized (1 was mis-randomized, never took any study drug and
was excluded from data analyses) to study treatments: licogliflozin
2.5 mg (n = 15), licogliflozin 10 mg (n = 16), licogliflozin 50 mg
(n = 31), empagliflozin 25 mg (n = 30) and placebo (n = 33; Figure S1).
Of the 125 patients randomized in the study, 75 were discontinued
due to early study termination, with 44 patients completing the
12-week study. Three patients permanently discontinued from study
treatment due to AEs. Two patients died (one death in each of the
licogliflozin 10 mg and placebo groups—not considered to be study-
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drug related) while a third patient discontinued from the empagliflozin
group due to increased blood creatinine levels.
The median age of the patients was 70.0 years (interquartile
range: 62.0–74.0) and most were male (71.8%), Caucasian (91.1%)
and enrolled in Europe (70.2%; Table 1). An LVEF of <45% was
observed in approximately 25% of patients. Baseline NT-proBNP
was comparable in all groups with the exception of the licogliflozin
50 mg group, where the median baseline value was substantially
lower (605 pg/mL 50 mg licogliflozin vs >890 pg/mL in all other
groups). For full details on smoking status, comorbidities, concomi-
tant medications and anti-diabetic medications by treatment group,
see Appendix (Tables S1, S2).
3.2 | Effect of licogliflozin, placebo or
empagliflozin on NT-proBNP following 12-weeks of
treatment
A numerical reduction in NT-proBNP from baseline was seen over
time in both licogliflozin and empagliflozin groups vs placebo, which
was apparent at week 4 and continued up to week 12 (Table S3). Due
to early study termination, limited data were available.
The greatest overall effect on NT-proBNP was observed at
week 12 for all licogliflozin groups vs placebo or empagliflozin
(Figure 2). However, statistical significance was only observed for
the licogliflozin 10 mg group vs placebo at week 12 (geometric
mean ratio 0.56 [95% confidence interval: 0.33, 0.95]; P = .033).
An apparent reduction in NT-proBNP from baseline was also seen
in the 50 mg licogliflozin group compared to placebo at week
12, but this failed to reach statistical significance (geometric mean
ratio 0.64 [95% confidence interval: 0.40, 1.03]; P = .064;
Table S3). These results were derived from the mixed effect model
of repeated measures, as described in the statistical analysis
section.
3.3 | Effect of licogliflozin, placebo or
empagliflozin on secondary endpoints after 12-weeks
of treatment
A summary of the descriptive analysis of the 12-week change from
baseline in secondary endpoints of main interest is shown in
Table 2, with the remaining secondary endpoint data shown in
Table S4.
3.3.1 | Glycaemic parameters
Numerically, the greatest reduction in HbA1c was observed with
licogliflozin 50 mg (change from baseline for licogliflozin 50 mg,
empagliflozin, and placebo were −0.58 ± 0.34%; −0.44 ± 1.18%),
and −0.04 ± 0.91%, respectively). A numerical reduction in FPG
was observed in all licogliflozin treatment groups at week 12, an
effect that was also apparent in empagliflozin and placebo groups
(Table 2).
3.3.2 | Body weight
Body weight numerically decreased by ~1 kg by week 4 in both
licogliflozin and empagliflozin groups (change from baseline
−0.60 ± 2.27 kg for licogliflozin 2.5 mg, n = 14; −0.99 ± 1.65 kg for
licogliflozin 10 mg, n = 15; −1.38 ± 2.00 for licogliflozin 50 mg, n = 28;
−1.44 ± 1.70 kg for empagliflozin, n = 26), with a slight increase in
body weight in the placebo group (2.62 ± 15.22 kg; n = 31). Weight
stabilized by week 12 in the licogliflozin 2.5 mg group, with additional
weight reduction seen in the other active treatment groups. Body
weight in the placebo group at week 12 was approximately the same
as that at baseline (Table 2).
3.3.3 | Change in blood pressure
An almost 10 mmHg reduction in SBP was seen in the licogliflozin
50 mg group at 12 weeks (−9.54 ± 16.88), with reductions of
−6.98 ± 15.03 mmHg and −2.85 ± 11.97 mmHg observed with
empagliflozin and placebo. Similar effects were noted for DBP, with
the greatest reduction in DBP seen in the licogliflozin 50 mg group
(−4.46 ± 11.24) vs empagliflozin (−1.81 ± 10.42 mmHg) and placebo
(−2.00 ± 8.60 mmHg; Table 2).
3.3.4 | Fasting lipid profile and hsCRP
No consistent pattern was observed for change from baseline to week
12 for any of the lipid parameters or hsCRP across the active treat-
ment groups.
Triglyceride levels were numerically increased from baseline at
week 12 across all groups with the exception of licogliflozin 2.5 mg
and placebo (Table S4). With the exception of the licogliflozin 10 mg
group, total cholesterol increased across all groups at week 12. High-
density lipoprotein–cholesterol increased in all treatment groups at
week 12, except for the licogliflozin 10 mg group and placebo. Low-
density lipoprotein–cholesterol also increased in all groups with the
exception of the placebo group, which showed a small decrease at
week 12 (Table S4).
3.3.5 | Echocardiography and change in NYHA
class
Changes in LVEF from baseline at week 12 were small and inconsis-
tent, while no significant changes in left atrial size and volume were
observed at week 12 (Table S4).
NYHA class improved for ~6–13% of patients across treatment
groups by week 4, with the exception of the licogliflozin 2.5 mg
group. At the same time, 2 of the patients (~8%) worsened in the
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TABLE 1 Key patient baseline characteristics
Characteristic
Licogliflozin
2.5 mg n = 15
Licogliflozin
10 mg n = 16
Licogliflozin
50 mg n = 30
Empagliflozin
25 mg n = 30 Placebo n = 33
Age
Median 70.0 72.5 66.0 68.5 71.0
IQR 62.0–75.0 66.0–75.5 60.0–71.0 62.0–74.0 59.0–74.0
Female, n (%)a 1 (6.7) 4 (25.0) 6 (20.0) 10 (33.3) 14 (42.4)
Race, n (%)a
Caucasian 14 (93.3) 14 (87.5) 28 (93.3) 28 (93.3) 29 (87.9)
Black 0 0 0 0 1 (3.0)
Asian 1 (6.7) 2 (12.5) 2 (6.7) 1 (3.3) 3 (9.1)
Native American 0 0 0 0 0
Pacific islander 0 0 0 0 0
Unknown 0 0 0 0 0
Other 0 0 0 1 (3.3) 0
Weight (kg)
Median 99.0 90.0 94.0 87.4 87.3
IQR 77.5–114.9 78.8–106.2 87.0–104.2 76.0–107.4 79.0–97.2
BMIb (kg/m2)
Median 33.3 31.9 32.0 31.2 31.3
IQR 28.1–37.5 29.2–35.9 29.1–37.7 28.8–34.7 28.4–34.2
SBP (mmHg)
Median 134.3 134.2 130.8 131.0 128.0
IQR 125.0–138.7 121.0–143.3 117.3–138.7 120.7–139.7 119.3–134.7
DBP (mmHg)
Median 75.7 78.7 75.7 76.3 73.3
IQR 72.3–85.0 73.7–83.3 70.0–82.0 73.0–80.3 64.7–79.0
eGFR (mL/min/1.73m2)
Median 76.3 61.3 69.8 63.5 66.5
IQR 50.7–91.3 58.6–72.2 53.6–77.8 56.9–73.1 55.5–78.8
LVEF (%; n) 14 16 30 27 30
Median 52.4 55.7 56.2 53.9 55.4
IQR 43.5–63.1 42.0–69.8 45.3–66.6 45.4–63.7 43.4–61.8
LVEF group, n (%)a
<45% 5 (33.3) 4 (25.0) 6 (20.0) 7 (23.3) 8 (24.2)
≥45% 10 (66.7) 12 (75.0) 24 (80.0) 23 (76.7) 25 (75.8)
NYHA class, n (%)a
I 0 0 0 0 0
II 13 (86.7) 14 (87.5) 26 (86.7) 22 (73.3) 25 (75.8)
III 2 (13.3) 2 (12.5) 3 (10.0) 8 (26.7) 8 (24.2)
IV 0 0 1 (3.3) 0 0
NT-proBNP (pg/mL)
Median 1129.0 945.0 605.0 978.5 894.0
IQR 682.0–1891.0 577.5–1725.5 518.0–927.0 649.0–1292.0 477.0–1447.0
All baseline characteristics were assessed at baseline unless otherwise indicated;
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial
infarction; n, number; NYHA, New York Heart Association; NT-proBNP, N-terminal pro b-type natriuretic peptide; SBP, systolic blood pressure; IQR,
interquartile range.
aPercentages were calculated from the total number of patients in each treatment group.
bAssessed at screening.
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licogliflozin 50 mg treatment group. Similar results were seen at week
12 (Table S4), although the sample size was smaller compared to
baseline or week 4.
3.4 | Safety
The safety profile of licogliflozin in this study is in line with previous
reports, with the exception that the rate of diarrhoea (4.9% in the
pooled licogliflozin groups) was lower than previously observed.18 The
overall incidence of AEs was comparable between the licogliflozin and
placebo groups, with a numerically higher incidence of AEs reported
in the empagliflozin group (at least 1 AE was reported in 73, 53 and
42% of the empagliflozin 25 mg, licogliflozin 50 mg and placebo
groups, respectively). Hypotension (6.5%), hypoglycaemia (8.1%), and
inadequate diabetes control (1.6%) were the most common adverse
events reported. Hypotension occurred in all treatment groups with
the exception of the licogliflozin 10 mg group. Four patients (one per
group, except licogliflozin 50 mg) experienced at least 1 clinically sig-
nificant hypoglycaemic event (plasma glucose <3.0 mmol/L). No
ketoacidosis events were reported. The incidence of bone fractures
was low (reported in 1 patient in the licogliflozin 50 mg group, and in
1 patient in the empagliflozin group). Genital mycotic infection was
reported in only 1 patient in the licogliflozin 10 mg group. Urinary
tract infections were reported in 3 patients; 1 patient in the
licogliflozin 2.5 mg group, 1 in the licogliflozin 10 mg group and 1 in
the placebo group. The incidence of serious AEs was slightly higher in
the empagliflozin group than the placebo or licogliflozin groups
(Table 3).
No obvious changes in biochemistry or urinalysis markers were
seen between licogliflozin, empagliflozin and placebo treatment arms.
The change from baseline in key laboratory evaluations at week 12 is
shown inTable S5.
4 | DISCUSSION
Coinhibition of SGLT1 and 2 with licogliflozin for 12 weeks in patients
with T2DM and HF led to reductions in NT-proBNP, a biomarker of
cardiac wall stress with an established relationship to HF severity and
prognosis.27-29 A significant effect was only observed with 10 mg
licogliflozin, although a nonsignificant trend (P = .064) was also seen
with the 50 mg dose. Due to the small sample sizes, our results cannot
be considered conclusive. Larger studies are therefore required to
F IGURE 2 Change from baseline in
N-terminal pro b-type natriuretic peptide
(NT-proBNP; geometric mean ratio)
following 4 weeks and 12 weeks'
treatment. A, NT-proBNP ratio vs
placebo, B, NT-proBNP ratio vs
empagliflozin. Values are expressed as
ratios (licogliflozin vs placebo or
empagliflozin) of endpoint/baseline
geometric means ±95% confidence
interval; *P < .05. #obs., number of
observations used in the model (for a
given time-point)
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TABLE 2 The effect of 12-weeks treatment with licogliflozin (change from baseline) on key efficacy parameters (secondary endpoint) vs
empagliflozin and placebo
Parametera, n mean (SD) Licogliflozin 2.5 mg Licogliflozin 10 mg Licogliflozin 50 mg Empagliflozin 25 mg Placebo
HbA1c %, n 9 8 12 14 18
Mean (SD) −0.29 (0.84) −0.01 (0.51) −0.58 (0.34) −0.44 (1.18) −0.04 (0.91)
FPG mmol/L, n 8 6 12 13 15
Mean (SD) −1.02 (1.04) −2.04 (4.98) −0.43 (2.15) −1.30 (2.44) −1.19 (3.97)
Body weight kg, n 9 8 13 14 18
Mean (SD) −0.78 (2.73) −1.83 (1.40) −2.15 (2.40) −2.25 (1.89) −0.34 (2.12)
BP mmHg, n 9 8 13 14 18
Mean SBP (SD) 5.15 (13.48) 0.17 (15.37) −9.54 (16.88) −6.98 (15.03) −2.85 (11.97)
Mean DBP (SD) −2.00 (6.58) 4.50 (12.75) −4.46 (11.24) −1.81 (10.42) −2.00 (8.60)
BP, blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose, HbA1c, glycated haemoglobin, SBP, systolic blood pressure; SD, standard
deviation.
To convert values for HbA1c to mmol/mol, multiply by 10.93 and then subtract 23.50.
aChange from baseline.
TABLE 3 Treatment emergent serious adverse events (SAEs) by primary system organ class and preferred term
Primary system organ class
preferred term
Licogliflozin 2.5 mg
n (%) n = 15
Licogliflozin 10 mg
n (%) n = 16
Licogliflozin 50 mg
n (%) n = 30
Empagliflozin 25 mg
n (%) n = 30
Placebo n
(%) n = 33
Number of patients with at least
1 SAE
2 (13.3) 2 (12.5) 3 (10.0) 5 (16.7) 3 (9.1)
Cardiac disorders 1 (6.7) 1 (6.3) 1 (3.3) 2 (6.7) 2 (6.1)
Angina pectoris 0 0 0 1 (3.3) 0
Atrial fibrillation 0 0 0 1 (3.3) 0
Cardiac failure 1 (6.7) 0 0 0 1 (3.0)
Cardiac failure chronic 0 0 1 (3.3) 0 0
Cardiac failure congestive 0 0 0 0 1 (3.0)
Coronary artery disease 0 1 (6.3) 0 1 (3.3) 0
General disorders and
administration site conditions
0 1 (6.3) 0 0 0
Cardiac death 0 1 (6.3) 0 0 0
Infections and infestations 1 (6.7) 0 1 (3.3) 1 (3.3) 0
Diarrhoea infections 1 (6.7) 0 0 0 0
Gastroenteritis 0 0 0 1 (3.3) 0
Wound infection 0 0 1 (3.3) 0 0
Injury, poisoning and procedural
complications
0 0 0 2 (6.7) 0
Hip fracture 0 0 0 1 (3.3) 0
Wound dehiscence 0 0 0 1 (3.3) 0
Nervous system disorders 0 0 1 (3.3) 0 0
Cerebral vascular occlusion 0 0 1 (3.3) 0 0
Reproductive system and breast
disorders
0 0 0 1 (3.3) 0
Benign prostatic hyperplasia 0 0 0 1 (3.3) 0
Respiratory, thoracic and
mediastinal disorders
0 0 0 0 1 (3.0)
Respiratory failure 0 0 0 0 1 (3.0)
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confirm these findings. The beneficial effects of SGLT2 inhibitors on
NT-proBNP have previously been reported in patients withT2DM fol-
lowing treatment with canagliflozin30 and dapagliflozin,31 although
the treatment durations were longer than in the current study
(104 and 24 weeks respectively) and the patient population was pre-
dominantly free from cardiac disease. Furthermore, canagliflozin did
not lead to a reduction in NT-proBNP but prevented an increase in
NT-proBNP that was seen in the placebo group at 2 years.30 The
effects on NT-proBNP levels observed with licogliflozin-associated
SGLT1 and 2 inhibition is in line with these assertions.
While the significant CV benefits of SGLT2 inhibitors are well
documented in the EMPA-REG OUTCOME, CANVAS and DECLARE
studies,7-9 it should be noted that very few patients with established
HF were enrolled in either the EMPA-REG OUTCOME study or CAN-
VAS program. The first study completed in patients with HF with
reduced ejection fraction treated with the SGLT2 inhibitor,
dapagliflozin (DAPA-HF) was recently reported, showing a 26% rela-
tive reduction in the composite of CV death, hospitalization for HF, or
urgent HF visit (P < .001). When analysed separately, HF hospitaliza-
tions were reduced by 30%, while CV mortality was reduced by 18%.
The DAPA-HF study provides the first compelling data that SGLT2
inhibition benefits patients with HFrEF, both in patients with and
without T2DM.32
The results of other ongoing studies in HF (EMPEROR-Reduced,
EMPEROR-Preserved and DELIVER) will provide further evidence on
the potential efficacy of SGLT2 inhibitors in patients with this condi-
tion.14,15,17 CV outcomes associated with SGLT1 and 2 inhibitor-
associated reductions in NT-proBNP have not yet been assessed.
However, ongoing trials are evaluating the effects of the SGLT1/2
inhibitor, sotagliflozin, on CV outcomes in high-risk patients with
T2DM and renal impairment (SCORED)33 and in patients with T2DM
and worsening HF (SOLOIST-WHF).34 Observations from phase II
studies of NT-proBNP in HF suggest that a 12-week treatment dura-
tion is sufficient to reveal a significant change in this biomarker.35
While the low patient numbers in our study precluded any assessment
of dose response, the significant reduction from baseline in NT-
proBNP at 12 weeks following treatment with licogliflozin 10 mg sug-
gests that SGLT1/2 inhibitors could lead to potential CV benefits.
However, larger studies with long follow-up are needed to evaluate
their impact on CV outcomes. Previous studies have established a
dose-effect relationship for licogliflozin on UGE in patients with
T2DM18 and on body weight in patients with obesity.18,36 While a
dose-effect of licogliflozin could not be established in this study, sec-
ondary effects of licogliflozin on HbA1c, UGE and body weight are
consistent with previous reports where a dose-effect relationship was
established.18,36 A potential dose-effect in patients with T2DM and
HF requires further investigation.
Other mechanisms have been proposed for the beneficial CV
effects of SGLT2 inhibitors, including reduced insulin resistance and
blood glucose levels, weight loss and reduced visceral fat, reduced
blood pressure, reduced arterial stiffness, and reduced inflammation
and oxidative stress.37 SGLT2 inhibitors have been associated with
reductions in HbA1c, blood pressure, body weight and other
metabolic parameters.38-41 While the effect differences between
SGLT1 and 2 inhibition vs SGLT2 alone are uncertain, it has been
suggested that dual inhibition would lead to a marked increase in
UGE, with a further reduction in HbA1c.37 The numerical changes
from baseline at week 12 in HbA1c and body weight observed in the
current study suggests that licogliflozin could lead to meaningful
reductions in these parameters. These observations are supported by
a previous study in patients with T2DM and in patients with obe-
sity18 and are also in line with earlier observations of a reduction in
HbA1c and body weight in studies with SGLT2 inhibitors.38-41 While
reductions in HbA1c and body weight are not thought to be the
leading factors responsible for the CV benefit seen in the EMPA-REG
OUTCOME study, weight loss could potentially be a contributing fac-
tor to the progressive reduction in CV mortality and HF seen over
1–3 years.8,37
The numerical reduction in SBP with licogliflozin 50 mg also has
potential benefit in this patient population and is consistent with the
findings of a recent meta-analysis study with SGLT2 inhibitors, show-
ing a 4 mmHg reduction in SBP and a 1.7 mmHg reduction in DBP.41
The SBP reduction observed with licogliflozin 50 mg was numerically
greater than that with empagliflozin, which is noteworthy. SBP was
also reduced (~5 mmHg) in the EMPA-REG OUTCOME study, which
could at least partly explain the beneficial CV outcome in this study.8
The observation of SGLT1 expression in the heart, suggests detailed
studies are needed to rule out any cardiac adverse effects of dual inhi-
bition.21,24 Human SGLT1 has more recently been associated with
several extra-renal effects (including entero-endocrine and cardiac
effects), which may provide CV benefit. However, the role of SGLT1
in these tissues remains to be determined.20
The most common AEs associated with SGLT2 inhibition or dual
SGLT1 and 2 inhibition are mycotic infections (only reported in
1 patient in this study).18,20,38-41 Gastrointestinal AEs are commonly
reported following treatment with both sotagliflozin and
licogliflozin,18,20 while clinical trials with sotagliflozin have also raised
concerns around the risk of hypoglycaemia and diabetic
ketoacidosis.43 No new safety signals were reported in this study,
with most AEs limited and mild in nature. The licogliflozin dose was
not taken around mealtime to minimize the risk of gastrointestinal
adverse effects of SGLT1 inhibition in the gut, such as diarrhoea, as
previously reported.18 Clinically significant hypoglycaemic events
were only reported in 4 patients, while no ketoacidosis events were
reported. SGLT2 inhibitors are also associated with an increased risk
of urinary tract infections (UTIs), volume depletion, fractures and
amputations.37 The incidence of hypotension, bone fractures and UTIs
in the current study was low and numerically similar between treat-
ment groups. The 2 deaths reported in the study were evaluated as
not related to the study drug. Longer-term studies with larger groups
are required to confirm these preliminary observations.
One of the major limitations of this study is the small sample size,
which was caused by study early termination due to slow enrolment.
A second limitation for a study of this size is patient randomization
into 5 groups, with early study termination resulting in a mostly
descriptive presentation of the results and preventing direct
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comparison with the SGLT2 inhibitor, empagliflozin. For many out-
come measures, the sample sizes at weeks 4 and 12 are significantly
(up to 50%) smaller than those at baseline. Our findings should there-
fore be interpreted with caution. The early termination of this study
also means that there is extremely limited data available at the longer-
duration 36-week time point, which is therefore not reported.
In conclusion, treatment with licogliflozin, an SGLT1 and 2 inhibi-
tor may have a positive impact on NT-proBNP in patients with T2DM
and HF. Clearly, larger and longer trials with dual SGLT1 and 2 inhibi-
tors would be required to validate if such drugs may have benefits in
patients withT2DM and HF.
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